Pharmaceuticals, Biotechnology and Life Sciences
Enhanced dystrophin expression in multiple muscle tissues and sustained functional benefit in DMD disease model following single low dose Data…
– BT5528 optimized to have distinct physiochemical and in vivo properties thought to enable more favorable preclinical safety, efficacy profiles…
Industry leaders connecting patient advocacy organizations in virtual approach ROCHESTER, N.Y. & PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #AdvocacyExchange–In light of the COVID-19…
Nature Biotechnology Publishes Comprehensive Description and Validation of the GeoMx Digital Spatial Profiler Using both nCounter & NGS Read Outs…
— Study met primary endpoint of time to neutrophil engraftment — — Omidubicel represents potential transformative treatment option for patients…
Neurocrine Biosciences has exercised its option to license the global rights to Idorsia’s ACT-709478, as it plans to initiate a Phase 2 study with this potent, selective, orally-active and brain penetrating T-type calcium channel blocker for the treatment of a rare pediatric epilepsy in the second half of 2020.
Te U.S. Food and Drug Administration (FDA) approved the myChoice CDx test for use as a companion diagnostic by healthcare professionals to identify certaikn advanced ovarian cancer patients.
Novavax said Monday that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of NVX-CoV2373, Novavax’ coronavirus vaccine candidate against SARS-CoV-2.
Amryt has reported $44.6M unaudited Q1 revenues representing 30% for the first quarter ended March 31, 2020. The net loss for the period was $17.0M, compared to 2.8 in the same period last year.
Sterling Pharma has announced a partnership with Accord Healthcare to secure the UK supply chain for Hydroxychloroquine (HCQ), a medication currently under investigation for the prevention and treatment of COVID-19.